NGeneBio Past Earnings Performance
Past criteria checks 0/6
NGeneBio's earnings have been declining at an average annual rate of -11.6%, while the Biotechs industry saw earnings growing at 7.2% annually. Revenues have been declining at an average rate of 16.1% per year.
Key information
-11.6%
Earnings growth rate
-9.2%
EPS growth rate
| Biotechs Industry Growth | 11.7% |
| Revenue growth rate | -16.1% |
| Return on equity | -109.6% |
| Net Margin | -266.3% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
No updates
Revenue & Expenses Breakdown
How NGeneBio makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 4,989 | -13,284 | 10,550 | 3,723 |
| 31 Mar 24 | 3,849 | -13,009 | 8,622 | 3,982 |
| 31 Dec 23 | 4,351 | -12,769 | 8,006 | 4,505 |
| 30 Sep 23 | 4,490 | -16,765 | 8,035 | 4,541 |
| 30 Jun 23 | 5,949 | -11,904 | 7,802 | 4,610 |
| 31 Mar 23 | 8,240 | -11,080 | 7,307 | 4,599 |
| 31 Dec 22 | 11,018 | -9,785 | 7,389 | 4,584 |
| 30 Sep 22 | 12,518 | -6,538 | 6,843 | 4,645 |
| 30 Jun 22 | 11,724 | -6,892 | 6,450 | 4,827 |
| 31 Mar 22 | 10,213 | -7,810 | 6,335 | 4,850 |
| 31 Dec 21 | 7,163 | -8,431 | 6,011 | 4,456 |
Quality Earnings: A354200 is currently unprofitable.
Growing Profit Margin: A354200 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if A354200's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare A354200's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A354200 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (6.1%).
Return on Equity
High ROE: A354200 has a negative Return on Equity (-109.65%), as it is currently unprofitable.